Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06958328 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

Study acronym: LAP100
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 322 → 333 locations Completion moved earlier from Oct 21, 2035 to Oct 21, 2030 · Interventions: Biopsy Procedure (Procedure), Biospecimen Collection (Procedure), Capecitabine (Drug), Computed Tomography (Procedure), Dose-escalated… to Biopsy Procedure (Procedure), Biospecimen Collection (Procedure), Capecitabine (Drug), Computed Tomography (Procedure), Dose-escalated… · Eligibility criteria expanded, about 135 words · 1 morev11 Show 4 more changesShow less
    • Completion moved earlier from Oct 21, 2035 to Oct 21, 2030
    • Interventions: Biopsy Procedure (Procedure), Biospecimen Collection (Procedure), Capecitabine (Drug), Computed Tomography (Procedure), Dose-escalated… to Biopsy Procedure (Procedure), Biospecimen Collection (Procedure), Capecitabine (Drug), Computed Tomography (Procedure), Dose-escalated…
    • Eligibility criteria expanded, about 135 words
    • Study description expanded, about 7 words

    See this version in full on ClinicalTrials.gov ↗

  2. Completion pushed from Oct 21, 2030 to Oct 21, 2035v10
  3. Trial sites expanded: 279 → 322 locationsv9
  4. Site details revised at 1 of 279 sitesv8
  5. Trial sites expanded: 242 → 279 locationsv7
Show 5 earlier versionsHide 5 earlier versions
  1. Study sites: 234 to 242 Interventions: Biopsy Procedure (Procedure), Biospecimen Collection (Procedure), Capecitabine (Drug), Computed Tomography (Procedure), Dose-escalated… to Biopsy Procedure (Procedure), Biospecimen Collection (Procedure), Capecitabine (Drug), Computed Tomography (Procedure), Dose-escalated… · Eligibility criteria expanded, about 190 words · Study description expanded, about 19 wordsv6 Show 3 more changesShow less
    • Interventions: Biopsy Procedure (Procedure), Biospecimen Collection (Procedure), Capecitabine (Drug), Computed Tomography (Procedure), Dose-escalated… to Biopsy Procedure (Procedure), Biospecimen Collection (Procedure), Capecitabine (Drug), Computed Tomography (Procedure), Dose-escalated…
    • Eligibility criteria expanded, about 190 words
    • Study description expanded, about 19 words

    See this version in full on ClinicalTrials.gov ↗

  2. Study sites: 186 to 234v5
  3. Study sites: 98 to 186v4
  4. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 98 · Start date changed from estimate of Oct 8, 2025 to Aug 21, 2025 · Interventions: Biopsy Procedure (Procedure), Biopsy Procedure (Procedure), Biospecimen Collection (Procedure), Biospecimen Collection (Procedure)… to Biopsy Procedure (Procedure), Biospecimen Collection (Procedure), Capecitabine (Drug), Computed Tomography (Procedure), Dose-escalated… · 3 morev3 Show 6 more changesShow less
    • Study sites: 0 to 98
    • Start date changed from estimate of Oct 8, 2025 to Aug 21, 2025
    • Interventions: Biopsy Procedure (Procedure), Biopsy Procedure (Procedure), Biospecimen Collection (Procedure), Biospecimen Collection (Procedure)… to Biopsy Procedure (Procedure), Biospecimen Collection (Procedure), Capecitabine (Drug), Computed Tomography (Procedure), Dose-escalated…
    • Secondary endpoints: details revised at 1 of 5 entries
    • Study description expanded, about 13 words
    • Eligibility criteria shortened, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  5. Start date: Jul 15, 2025 to Oct 8, 2025v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
NRG Oncology
67 trials monitored
See 5 trials at risk
Pancreatic Cancer
1,639 trials monitored
See 91 trials at risk
This phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-8 months of chemotherapy. Usual care options include additional chemotherapy, observation, or standard lower-dose radiation therapy. These treatments may delay tumor growth but have not been shown to improve survival. Radiation therapy uses high energy X-rays to kill cancer cells and shrink tumors. Dose-escalated radiation therapy involves the precise delivery of higher doses to the tumor, often over a shorter period of time. This trial assesses whether using dose-escalated radiation therapy can prolong survival.
Trial Details
NCT Number NCT06958328
Lead Sponsor NRG Oncology
Conditions Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Enrollment 356 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov